

Lab: CPHL		HIV-DR Accession Number: HIVDR-2234-23		Art Number: 695		Form Number: 113794588	
				Viral Load			
Collection date: 2023-10-06		VL test date: 2023-10-12		VL copies: 11,239 Copies / mL		Facility: Wekomiire H/C III (St Thereza)	
				HIV DR			
Sample Type: P		HIV-DR test date: 2023-12-02		Release date: 2023-12-11 13:43:11		Amplification Status: Amplified	
				Sequence Summary			
Genes Analysed: IN, PR, RT		HIV-1 Subtype: G		Regimen at time of DR test: AZT+3TC+DTG		Treatment Line: Second Line	
				Drug resistance interpretation			
Drug Name		Code		Resistance Level		Score	
		Protease Inhibitors					
Atazanavir	ATV			Susceptible		0	
Darunavir	DRV			Susceptible		0	
Fosamprenavir	FPV			Susceptible		0	
Indinavir	IDV			Susceptible		0	
Lopinavir	LPV			Susceptible		0	
Nelfinavir	NFV			Susceptible		0	
Saquinavir	SQV			Susceptible		0	
Tipranavir	TPV			Susceptible		0	
				Nucleoside Reverse Transcriptase Inhibitors			
Abacavir	ABC			Low-Level Resistance		15	
Azidothymidine	AZT			Susceptible		-10	
Stavudine	D4T			Susceptible		-10	
Didanosine	DDI			Potential Low-Level Resistance		10	
Emtricitabine	FTC			High-Level Resistance		60	
Lamivudine	LMV			High-Level Resistance		60	
Tenofovir	TDF			Susceptible		-10	
				Non-nucleoside Reverse Transcriptase Inhibitors			
Doravirine	DOR			Low-Level Resistance		15	
Efavirenz	EFV			Low-Level Resistance		15	
Etravirine	ETR			Potential Low-Level Resistance		10	

Lab: CPHL	HIV-DR Accession Number: HIVDR-2234-23		Art Number:695	Form Number: 113794588
Viral Load				
Collectiondate: 2023-10-06	VL test date: 2023-10-12		VL copies: 11,239 Copies / mL	Facility: Wekomiire H/C III (St Thereza)
HIV DR				
Sample Type:P	HIV-DR test date: 2023-12-02		Release date: 2023-12-11 13:43:11	Amplification Status: Amplified
Sequence Summary				
Genes Analysed: IN, PR, RT	HIV-1 Subtype: G		Regimen at time of DR test: AZT+3TC+DTG	Treatment Line: Second Line
Drug resistance interpretation				
Drug Name	Code		Resistance Level	Score
Drug Class	Comments			
Drug Class	Mutations at $\geq 20\%$		Mutations at $20\%$	
Approved & Released By	Release Date		Printed By	Date Printed
Nevirapine	NVP		Intermediate Resistance	30
Rilpivirine	RPV		Low-Level Resistance	15
Integrase Strand Transfer Inhibitors				
Bictegravir	BIC		Intermediate Resistance	30
Cabotegravir	CAB		High-Level Resistance	60
Dolutegravir	DTG		Intermediate Resistance	50
Elvitegravir	EVG		High-Level Resistance	60
Raltegravir	RAL		High-Level Resistance	60
Comments				
Drug Class	Comments			
RT - NNRTI	A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.			
RT - NRTI	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.			

<b>Lab: CPHL</b>	<b>HIV-DR Accession Number: HIVDR-2234-23</b>	<b>Art Number:695</b>	<b>Form Number: 113794588</b>
Viral Load			
<b>Collectiondate: 2023-10-06</b>	<b>VL test date: 2023-10-12</b>	<b>VL copies: 11,239 Copies / mL</b>	<b>Facility: Wekomiire H/C III (St Thereza)</b>
HIV DR			
<b>Sample Type:P</b>	<b>HIV-DR test date: 2023-12-02</b>	<b>Release date: 2023-12-11 13:43:11</b>	<b>Amplification Status: Amplified</b>
Sequence Summary			
<b>Genes Analysed: IN, PR, RT</b>	<b>HIV-1 Subtype: G</b>	<b>Regimen at time of DR test: AZT+3TC+DTG</b>	<b>Treatment Line: Second Line</b>
Drug resistance interpretation		<b>Resistance Level</b>	<b>Score</b>
<b>Drug Name</b>	<b>Code</b>		
Drug Class	Comments		
<b>Drug Class</b>	<b>Mutations at <math>\geq 20\%</math></b>	<b>Mutations at 20%</b>	
<b>Approved &amp; Released By</b>	<b>Release Date</b>	<b>Printed By</b>	<b>Date Printed</b>
Drug Class	Comments		
<b>Drug Class</b>	<b>Mutations at <math>\geq 20\%</math></b>	<b>Mutations at 20%</b>	
<b>Approved &amp; Released By</b>	<b>Release Date</b>	<b>Printed By</b>	<b>Date Printed</b>
PI - MAJOR			
PI - ACCESSORY			
INSTI - MAJOR			
<p>G118R is a nonpolymorphic mutation reported in a significant proportion of persons with VF and emergent HIVDR in persons receiving a DTG-containing regimen. It has occasionally been reported in persons receiving other INSTIs. It is associated with 5-10-fold reduced susceptibility to RAL, EVG, DTG and CAB, and 2-3 fold reduced susceptibility to BIC.</p>			
INSTI - ACCESSORY			
Mutations			
<b>Drug Class</b>	<b>Mutations at <math>\geq 20\%</math></b>	<b>Mutations at 20%</b>	
PI			
NRTI	M184V(97.02%)	D67G(1.28%),Y115F(2.66%)	
NNRTI	A98G(98.32%)		
INSTI	G118R(98.69%)	Q95K(1.03%),S230R(1.55%)	
Official Use			
<b>Approved &amp; Released By</b>	<b>Release Date</b>	<b>Printed By</b>	<b>Date Printed</b>

Mr. Admin  
Admin Admin 2024-02-14 18:58:43

Admin 2024-02-14  
18:58:43